Cargando…

Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration

Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, Leila, Bowen, Gloria, Mertens, Benjamin, Denson, Keelie, Jordan, Kathleen, Vidakovic, Branislav, Mitchell, Cassie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016647/
https://www.ncbi.nlm.nih.gov/pubmed/31936812
http://dx.doi.org/10.3390/bs10010033
_version_ 1783497023111036928
author Bond, Leila
Bowen, Gloria
Mertens, Benjamin
Denson, Keelie
Jordan, Kathleen
Vidakovic, Branislav
Mitchell, Cassie S.
author_facet Bond, Leila
Bowen, Gloria
Mertens, Benjamin
Denson, Keelie
Jordan, Kathleen
Vidakovic, Branislav
Mitchell, Cassie S.
author_sort Bond, Leila
collection PubMed
description Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, and supplements. Associations were assessed at p < 0.05 and p < 0.001 significance thresholds using applicable methods (Chi-square, t-test, ANOVA, logistical regression, random forests, Fisher’s exact test) within a retrospective cohort of 1585 patients. Factors significantly correlated with positive (happy or normal) mood included family support and usage of bi-level positive airway pressure (Bi-PAP) and/or cough assist. Decline in physical factors like presence of dysphagia, drooling, general pain, and decrease in ALSFRS-R total score or forced vital capacity (FVC) significantly correlated with negative (depressed or anxious) mood (p < 0.05). Use of antidepressants or pain medications had no association with ALS patient mood (p > 0.05), but were significantly associated with increased survival (p < 0.05). Positive patient mood, Bi-PAP, cough assist, percutaneous endoscopic gastrostomy (PEG), and accompaniment to clinic visits associated with increased survival duration (p < 0.001). Of the 47 most prevalent pharmaceutical and supplement categories, 17 associated with significant survival duration increases ranging +4.5 to +16.5 months. Tricyclic antidepressants, non-opioids, muscle relaxants, and vitamin E had the highest associative increases in survival duration (p < 0.05). Random forests, which examined complex interactions, identified the following pharmaceuticals and supplements as most predictive to survival duration: Vitamin A, multivitamin, PEG supplements, alternative herbs, antihistamines, muscle relaxants, stimulant laxatives, and antispastics. Statins, metformin, and thiazide diuretics had insignificant associations with decreased survival.
format Online
Article
Text
id pubmed-7016647
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70166472020-03-04 Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration Bond, Leila Bowen, Gloria Mertens, Benjamin Denson, Keelie Jordan, Kathleen Vidakovic, Branislav Mitchell, Cassie S. Behav Sci (Basel) Article Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, and supplements. Associations were assessed at p < 0.05 and p < 0.001 significance thresholds using applicable methods (Chi-square, t-test, ANOVA, logistical regression, random forests, Fisher’s exact test) within a retrospective cohort of 1585 patients. Factors significantly correlated with positive (happy or normal) mood included family support and usage of bi-level positive airway pressure (Bi-PAP) and/or cough assist. Decline in physical factors like presence of dysphagia, drooling, general pain, and decrease in ALSFRS-R total score or forced vital capacity (FVC) significantly correlated with negative (depressed or anxious) mood (p < 0.05). Use of antidepressants or pain medications had no association with ALS patient mood (p > 0.05), but were significantly associated with increased survival (p < 0.05). Positive patient mood, Bi-PAP, cough assist, percutaneous endoscopic gastrostomy (PEG), and accompaniment to clinic visits associated with increased survival duration (p < 0.001). Of the 47 most prevalent pharmaceutical and supplement categories, 17 associated with significant survival duration increases ranging +4.5 to +16.5 months. Tricyclic antidepressants, non-opioids, muscle relaxants, and vitamin E had the highest associative increases in survival duration (p < 0.05). Random forests, which examined complex interactions, identified the following pharmaceuticals and supplements as most predictive to survival duration: Vitamin A, multivitamin, PEG supplements, alternative herbs, antihistamines, muscle relaxants, stimulant laxatives, and antispastics. Statins, metformin, and thiazide diuretics had insignificant associations with decreased survival. MDPI 2020-01-10 /pmc/articles/PMC7016647/ /pubmed/31936812 http://dx.doi.org/10.3390/bs10010033 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bond, Leila
Bowen, Gloria
Mertens, Benjamin
Denson, Keelie
Jordan, Kathleen
Vidakovic, Branislav
Mitchell, Cassie S.
Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title_full Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title_fullStr Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title_full_unstemmed Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title_short Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
title_sort associations of patient mood, modulators of quality of life, and pharmaceuticals with amyotrophic lateral sclerosis survival duration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016647/
https://www.ncbi.nlm.nih.gov/pubmed/31936812
http://dx.doi.org/10.3390/bs10010033
work_keys_str_mv AT bondleila associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT bowengloria associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT mertensbenjamin associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT densonkeelie associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT jordankathleen associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT vidakovicbranislav associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration
AT mitchellcassies associationsofpatientmoodmodulatorsofqualityoflifeandpharmaceuticalswithamyotrophiclateralsclerosissurvivalduration